Preliminary Program

Sessions requiring tickets are noted throughout the 2017 ASCO Annual Meeting Preliminary Program ( = Ticketed Session). Learn more about adding the Ticketed Session package to your registration.

The Preliminary Program is current as of February 08, 2017. Discover more information on the different session types at the 2017 ASCO Annual Meeting.

7:30 AM–9:15 AM

Highlights of the Day Session

Highlights of the Day Session III

8:00 AM–9:15 AM

Education Sessions

Acute Myeloid Leukemia Subsets With Emerging Treatment Options

Richard M. Stone, MD—Chair

Dana-Farber Cancer Institute

Targeting Flt3 Mutations in Acute Myeloid Leukemia

Courtney Denton Dinardo, MD

The University of Texas MD Anderson Cancer Center

Role of IDH Mutations in Acute Myeloid Leukemia: A Valid Therapeutic Target?

Bruno C. Medeiros, MD

Stanford School of Medicine 

Biology and Therapy of Secondary Acute Myeloid Leukemia: Any Progress?

 

Diagnosis and Treatment of Prostate Cancer: What Americans Can Learn From International Oncologist

John Graham MB ChB, FRCR, FRCP

Musgrove Park Hospital

Have Decisions by the National Institute for Health and Care Excellence Affected Outcomes of British Patients With Metastatic Castration-Resistant Prostate Cancer?

Juergen Gschwend, MD

Technical University of Munich

How Advances in Molecular Imaging Have Changed Our Understanding of State and Stage of the Disease

Nicholas D. James, BSc, MBBS, PhD—Chair

Queen Elizabeth Hospital

How Randomized Trials of STAMPEDE Have Influenced Treatment Decisions in the United Kingdom

 

Panel Testing for Risk Management: High-, Medium-, and Low-Penetrance Genes 

Kara J. Milliron, MS, CGC—Chair

University of Michigan Comprehensive Cancer Center

Panel Gene Testing: Penetrance Versus Prevalence

Mark E. Robson, MD

Memorial Sloan Kettering Cancer Center 

Panel Testing Through a Lifespan: Thresholds for Actionability

Jessica Long, MS, CGC

Abramson Cancer Center at Penn Medicine

Practical Considerations of Panel Testing Results: VUS and Conversions

 

Rethinking Treatment of Rectal Cancer: Emergence of New Standards?

John Marshall, MD—Chair

George Lombardi Comprehensive Cancer Center, Georgetown University

Case Presentation and the Role of Neoadjuvant Chemotherapy

Chi Lin, MD, PhD

University of Nebraska Medical Center

Neoadjuvant Radiation: Long Course Versus Short Course Versus None

Larissa K. F. Temple, MD

Memorial Sloan Kettering Cancer Center

Surgical Management of Rectal Cancer: From Abdominal Perineal Resection/Low Anterior Resection to Local Resection to None

8:00 AM–9:30 AM

Clinical Science Symposium

Head and Neck Cancer

9:45 AM–11:00 AM

Education Sessions

Cascade Testing: What to Do When Ascertaining Germline Mutations From Tumor and Other Genomic Testing

Jeff Boyd, PhD—Chair

Florida International University

How to Interpret Tumor Genomics for the Oncologist

Jorge Reis-Filho, MD, PhD

Memorial Sloan Kettering Cancer Center

Relationship Between Tumor Subtypes, Organ of Origin, and Driver Genes: Moving Toward Integration

 

Challenging Multidisciplinary Head and Neck Tumor Board: Approaches to Oligometastatic, Locally Recurrent Cancer, and Widely Metastatic Disease

Barbara Burtness, MD—Chair

Yale Cancer Center

In Era of Immunotherapy and Targeted Therapies What Is the Most Appropriate Frontline Therapy and Beyond for Widely Metastatic Disease?

Anthony T. C. Chan, MD, FRCP

Chinese University of Hong Kong

Recurrent Metastatic Nasopharyngeal Carcinoma State-of-the-Art Treatment

Marc Cohen, MD, MPH

Memorial Sloan Kettering Cancer Center 

Carotid Blowout: Risk Assessment, Identification, and Management

 

Disparities in Screening and Treatment of Prostate Cancer for the Older Patient

William Dale, MD, PhD

University of Chicago Medicine

Key Interdisciplinary and Integrated Treatment Planning Necessary to Effectively Treat Older Adults With Prostate Cancer

Alberto Briganti, MD

Urological Research Institute

Does Prostate Cancer Presentation and Biologic Characteristics Differ in Older Patients?

Alicia Katherine Morgans, MD, MPH—Chair

Vanderbilt University Medical Center

Physical and Cognitive Effects of Systemic Therapy in Older Men With Prostate Cancer

 

Tumor-Agnostic Drug Approvals: In the Distant Future or Already Here?

Steven J. Lemery, MD, MHS—Chair

U.S. Food and Drug Administration

Regulatory Considerations Regarding Tissue-Agnostic Development

Keith Flaherty, MD

Massachusetts General Hospital

Target Selection for Trials of Tissue-Agnostic Drug Development

 Dung T. Le, MD

Johns Hopkins University

Approach to the Development of Drugs for Patients with MSI-H Tumors

9:45 AM–11:15 AM

 

Clinical Science Symposium

Gastrointestinal (Colorectal) Cancer

9:45 AM–12:45 PM

Oral Abstract Sessions

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Lung Cancer—Non-Small Cell Metastatic

11:30 AM–12:45 PM

Education Session

Overcoming Resistance to Immunotherapy

Jedd D. Wolchok, MD, PhD—Chair

Memorial Sloan Kettering Cancer Center

Rational Strategies for Immunotherapy Combinations

Thomas Gajewski, MD, PhD 

The University of Chicago

Understanding Mechanisms of Resistance to Immunotherapy in Solid Tumors

Jeffrey S. Weber, MD, PhD NYU

Langone Medical Center

Biomarker Assessment in Immunotherapy Trials